8-K: MEI Pharma Presents Promising Clinical Data for Voruciclib and ME-344 at Medical Symposium

MEI Pharma highlighted clinical data for its drug candidates voruciclib and ME-344, targeting resistance mechanisms in cancer therapies, at the Brookline Virtual MDS and AML Symposium.

Summary

• MEI Pharma presented clinical data on voruciclib, a CDK9 inhibitor, and ME-344, an OXPHOS inhibitor, at a medical symposium.
• Voruciclib is being evaluated in combination with venetoclax for relapsed/refractory acute myeloid leukemia (AML).
• Clinical data shows voruciclib has potential to address venetoclax resistance in AML.
• ME-344 is being developed in combination with anti-angiogenics like bevacizumab for solid tumors, particularly colorectal cancer.
• The company has sufficient cash to fund operations for at least the next 12 months, with $59.5 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
• A Phase 2 study arm for voruciclib in R/R AML is planned for 2025, pending FDA advice.
• The company is developing a new formulation of ME-344, with an update expected in the first half of 2025.

Sentiment

Score: 7

Explanation: The document presents promising clinical data for both voruciclib and ME-344, with a clear focus on addressing unmet needs in cancer treatment. The company's strong cash position and plans for future studies are also positive. However, there are some risks and uncertainties associated with drug development, which temper the overall sentiment.

Positives

• Voruciclib has shown encouraging results in AML patients, including those treated in combination with venetoclax.
• Voruciclib is a mutation-agnostic therapy, potentially addressing a larger percentage of the AML population.
• ME-344 has demonstrated clinical activity in combination with bevacizumab in metastatic colorectal cancer.
• The company has a strong cash position to fund operations for at least the next 12 months.
• Voruciclib has shown a decrease in Mcl-1 protein levels, indicating on-target biological activity.
• ME-344 has shown a decrease in the proliferation biomarker Ki67 in combination with bevacizumab.

Negatives

• Some patients experienced adverse events such as fatigue, abdominal pain, and diarrhea in the ME-344 study.
• The median progression-free survival (PFS) for ME-344 plus bevacizumab in metastatic colorectal cancer was 1.9 months.
• The median overall survival (OS) for ME-344 plus bevacizumab in metastatic colorectal cancer was 6.7 months.

Risks

• The company's actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• There are risks related to the successful commercialization of product candidates and obtaining FDA approval.
• The company faces risks related to competition, patent protection, and the need for additional financing.
• Clinical trial results may differ from reported interim data.
• There is uncertainty regarding the impact of rising inflation and interest rates.
• The company is dependent on collaboration or contractual arrangements for development and commercialization.

Future Outlook

The company plans to initiate a Phase 2 study arm for voruciclib in R/R AML in 2025 and expects a new formulation update for ME-344 in the first half of 2025. They believe their current cash balance is sufficient to fund operations for at least the next 12 months.

Management Comments

• Richard Ghalie, M.D., the Chief Medical Officer of MEI Pharma, Inc., will participate in a panel at the Brookline Virtual MDS and AML Symposium to discuss clinical data from the ongoing clinical evaluation of voruciclib.

Industry Context

The presentation highlights MEI Pharma's focus on addressing resistance mechanisms in cancer therapies, a significant area of unmet need in the oncology field. The company is targeting specific pathways like CDK9 and OXPHOS, which are relevant to the development of new cancer treatments. The use of combination therapies, such as voruciclib with venetoclax and ME-344 with bevacizumab, reflects a broader trend in oncology to improve treatment efficacy.

Comparison to Industry Standards

• The document references Venclexta sales of ~$2.3B in 2023, projected to grow to ~$3.3B by 2028, indicating the market size for venetoclax-based therapies.
• The document notes that CR+CRh/CRi rates for non-mutation targeted regimens range from 6-12.5% in patients previously exposed to venetoclax, highlighting the need for improved therapies like voruciclib.
• The document mentions that approximately 30%, 30% and 20% of AML patients have NPM1, FLT3 and IDH1/2 mutations, respectively, emphasizing the need for mutation-agnostic therapies like voruciclib.
• The document compares the 20% complete response rate with VORU+VEN in R/R AML to the 6-12.5% rate for non-mutation targeted regimens, suggesting a potential improvement.
• The document references a study showing that approximately 80% of patients with an NPM1 mutation had a co-mutation in either FLT3, IDH1/2 or both, highlighting the complexity of AML and the need for therapies that can address multiple mutations.

Stakeholder Impact

• Shareholders may view the clinical data and financial position positively.
• Employees may be encouraged by the progress of the drug candidates.
• Patients with AML and other cancers may benefit from the development of new treatment options.
• The company's suppliers and partners may see potential for future collaborations.

Next Steps

• Initiate a Phase 2 study arm for voruciclib in R/R AML in 2025.
• Determine the Recommended Phase 2 Dose and Schedule for voruciclib.
• Continue the Phase 1 evaluation of voruciclib plus venetoclax in R/R AML.
• Develop a new formulation of ME-344, with an update expected in H1 2025.

Key Dates

Keywords

Voruciclib, ME-344, AML, Acute Myeloid Leukemia, CDK9 Inhibitor, OXPHOS Inhibitor, Venetoclax, Bevacizumab, Colorectal Cancer, Oncology, Cancer Therapy, Clinical Trials